Edwards Lifesciences (NYSE: EW) reported Q3 EPS of $0.67, $0.08 better than the analyst estimate of $0.59. Revenue for the quarter came in at $1.55 billion versus the consensus estimate of $1.5 billion.

GUIDANCE:

Edwards Lifesciences sees FY2025 EPS of $2.56-$2.62, versus the consensus of $2.51.

Increasing sales growth guidance to high end of 9-10% from 9-10%
Increasing TAVR sales guidance to 7-8% from 6-7%

For earnings history and earnings-related data on Edwards Lifesciences (EW) click here.